| Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010 | 17249 | 2010 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1702 | 2017 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1191 | 2017 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 958 | 2012 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 770 | 2019 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 548 | 2018 |
| DNA vaccines: precision tools for activating effective immunity against cancer J Rice, CH Ottensmeier, FK Stevenson Nature Reviews Cancer 8 (2), 108-120, 2008 | 517 | 2008 |
| Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19 BJ Meckiff, C Ramírez-Suástegui, V Fajardo, SJ Chee, A Kusnadi, ... Cell 183 (5), 1340-1353. e16, 2020 | 493 | 2020 |
| Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer AP Ganesan, J Clarke, O Wood, EM Garrido-Martin, SJ Chee, T Mellows, ... Nature immunology 18 (8), 940-950, 2017 | 486 | 2017 |
| Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response P Kvistborg, D Philips, S Kelderman, L Hageman, C Ottensmeier, ... Science translational medicine 6 (254), 254ra128-254ra128, 2014 | 430 | 2014 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 421 | 2017 |
| Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer MJ Ward, SM Thirdborough, T Mellows, C Riley, S Harris, K Suchak, ... British journal of cancer 110 (2), 489-500, 2014 | 421 | 2014 |
| Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma D Zhu, H McCarthy, CH Ottensmeier, P Johnson, TJ Hamblin, ... Blood, The Journal of the American Society of Hematology 99 (7), 2562-2568, 2002 | 304 | 2002 |
| Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro Is Partly Mediated by CD44H SA Cannistra, GS Kansas, J Niloff, B DeFranzo, Y Kim, C Ottensmeier Cancer research 53 (16), 3830-3838, 1993 | 297 | 1993 |
| A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors E Angevin, J Tabernero, E Elez, SJ Cohen, R Bahleda, JL Van Laethem, ... Clinical Cancer Research 20 (8), 2192-2204, 2014 | 235 | 2014 |
| Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study S Mandruzzato, S Brandau, CM Britten, V Bronte, V Damuzzo, ... Cancer Immunology, Immunotherapy 65, 161-169, 2016 | 233 | 2016 |
| Response definition criteria for ELISPOT assays revisited Z Moodie, L Price, C Gouttefangeas, A Mander, S Janetzki, M Löwer, ... Cancer Immunology, Immunotherapy 59, 1489-1501, 2010 | 232 | 2010 |
| NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors K Ford, CJ Hanley, M Mellone, C Szyndralewiez, F Heitz, P Wiesel, ... Cancer research 80 (9), 1846-1860, 2020 | 219 | 2020 |
| DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer L Low, A Mander, K McCann, D Dearnaley, T Tjelle, I Mathiesen, ... Human gene therapy 20 (11), 1269-1278, 2009 | 216 | 2009 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ... The Lancet Oncology 22 (11), 1530-1540, 2021 | 213* | 2021 |
Johnson PWProfessor of Medical Oncology, University of Southampton在 soton.ac.uk 的电子邮件经过验证
